These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

303 related articles for article (PubMed ID: 23404788)

  • 1. Effects of taspoglutide on glycemic control and body weight in obese patients with type 2 diabetes (T-emerge 7 study).
    Hollander P; Lasko B; Barnett AH; Bengus M; Kanitra L; Pi-Sunyer FX; Balena R
    Obesity (Silver Spring); 2013 Feb; 21(2):238-47. PubMed ID: 23404788
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of taspoglutide in patients with type 2 diabetes inadequately controlled with metformin plus pioglitazone over 24 weeks: T-Emerge 3 trial.
    Henry RR; Mudaliar S; Kanitra L; Woloschak M; Balena R;
    J Clin Endocrinol Metab; 2012 Jul; 97(7):2370-9. PubMed ID: 22539590
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Treatment with the human once-weekly glucagon-like peptide-1 analog taspoglutide in combination with metformin improves glycemic control and lowers body weight in patients with type 2 diabetes inadequately controlled with metformin alone: a double-blind placebo-controlled study.
    Nauck MA; Ratner RE; Kapitza C; Berria R; Boldrin M; Balena R
    Diabetes Care; 2009 Jul; 32(7):1237-43. PubMed ID: 19366970
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Efficacy and safety of taspoglutide monotherapy in drug-naive type 2 diabetic patients after 24 weeks of treatment: results of a randomized, double-blind, placebo-controlled phase 3 study (T-emerge 1).
    Raz I; Fonseca V; Kipnes M; Durrwell L; Hoekstra J; Boldrin M; Balena R
    Diabetes Care; 2012 Mar; 35(3):485-7. PubMed ID: 22301126
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Efficacy and tolerability of taspoglutide versus pioglitazone in subjects with type 2 diabetes uncontrolled with sulphonylurea or sulphonylurea-metformin therapy: a randomized, double-blind study (T-emerge 6).
    Pratley RE; Urosevic D; Boldrin M; Balena R;
    Diabetes Obes Metab; 2013 Mar; 15(3):234-40. PubMed ID: 22958426
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and safety of LY3298176, a novel dual GIP and GLP-1 receptor agonist, in patients with type 2 diabetes: a randomised, placebo-controlled and active comparator-controlled phase 2 trial.
    Frias JP; Nauck MA; Van J; Kutner ME; Cui X; Benson C; Urva S; Gimeno RE; Milicevic Z; Robins D; Haupt A
    Lancet; 2018 Nov; 392(10160):2180-2193. PubMed ID: 30293770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of topiramate in combination with metformin in the treatment of obese subjects with type 2 diabetes: a randomized, double-blind, placebo-controlled study.
    Toplak H; Hamann A; Moore R; Masson E; Gorska M; Vercruysse F; Sun X; Fitchet M
    Int J Obes (Lond); 2007 Jan; 31(1):138-46. PubMed ID: 16703004
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of Subcutaneous Tirzepatide vs Placebo Added to Titrated Insulin Glargine on Glycemic Control in Patients With Type 2 Diabetes: The SURPASS-5 Randomized Clinical Trial.
    Dahl D; Onishi Y; Norwood P; Huh R; Bray R; Patel H; Rodríguez Á
    JAMA; 2022 Feb; 327(6):534-545. PubMed ID: 35133415
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eight weeks of treatment with long-acting GLP-1 analog taspoglutide improves postprandial insulin secretion and sensitivity in metformin-treated patients with type 2 diabetes.
    Gastaldelli A; Nauck MA; Balena R
    Metabolism; 2013 Sep; 62(9):1330-9. PubMed ID: 23831441
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Orlistat 120 mg improves glycaemic control in type 2 diabetic patients with or without concurrent weight loss.
    Jacob S; Rabbia M; Meier MK; Hauptman J
    Diabetes Obes Metab; 2009 Apr; 11(4):361-71. PubMed ID: 19207292
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safety and tolerability of high doses of taspoglutide, a once-weekly human GLP-1 analogue, in diabetic patients treated with metformin: a randomized double-blind placebo-controlled study.
    Ratner R; Nauck M; Kapitza C; Asnaghi V; Boldrin M; Balena R
    Diabet Med; 2010 May; 27(5):556-62. PubMed ID: 20536952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Long-term efficacy and safety of canagliflozin monotherapy in patients with type 2 diabetes inadequately controlled with diet and exercise: findings from the 52-week CANTATA-M study.
    Stenlöf K; Cefalu WT; Kim KA; Jodar E; Alba M; Edwards R; Tong C; Canovatchel W; Meininger G
    Curr Med Res Opin; 2014 Feb; 30(2):163-75. PubMed ID: 24073995
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Metabolic control and weight loss in patients with obesity and type 2 diabetes mellitus, treated with exenatide].
    Pujante Alarcón P; Hellín Gil MD; Román LM; Ferrer Gómez M; García Zafra MV; Tébar Massó J
    Med Clin (Barc); 2012 Dec; 139(13):572-8. PubMed ID: 22209597
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Use of sibutramine in overweight adult hispanic patients with type 2 diabetes mellitus: a 12-month, randomized, double-blind, placebo-controlled clinical trial.
    Sánchez-Reyes L; Fanghänel G; Yamamoto J; Martínez-Rivas L; Campos-Franco E; Berber A
    Clin Ther; 2004 Sep; 26(9):1427-35. PubMed ID: 15531005
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Weight loss, HbA1c reduction, and tolerability of cetilistat in a randomized, placebo-controlled phase 2 trial in obese diabetics: comparison with orlistat (Xenical).
    Kopelman P; Groot Gde H; Rissanen A; Rossner S; Toubro S; Palmer R; Hallam R; Bryson A; Hickling RI
    Obesity (Silver Spring); 2010 Jan; 18(1):108-15. PubMed ID: 19461584
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Latin-American trial of orlistat for weight loss and improvement in glycaemic profile in obese diabetic patients.
    Halpern A; Mancini MC; Suplicy H; Zanella MT; Repetto G; Gross J; Jadzinsky M; Barranco J; Aschner P; Ramirez L; Matos AG
    Diabetes Obes Metab; 2003 May; 5(3):180-8. PubMed ID: 12681025
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Randomized placebo-controlled clinical trial of lorcaserin for weight loss in type 2 diabetes mellitus: the BLOOM-DM study.
    O'Neil PM; Smith SR; Weissman NJ; Fidler MC; Sanchez M; Zhang J; Raether B; Anderson CM; Shanahan WR
    Obesity (Silver Spring); 2012 Jul; 20(7):1426-36. PubMed ID: 22421927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of adding exenatide to a thiazolidinedione in suboptimally controlled type 2 diabetes: a randomized trial.
    Zinman B; Hoogwerf BJ; Durán García S; Milton DR; Giaconia JM; Kim DD; Trautmann ME; Brodows RG
    Ann Intern Med; 2007 Apr; 146(7):477-85. PubMed ID: 17404349
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study.
    Moretto TJ; Milton DR; Ridge TD; Macconell LA; Okerson T; Wolka AM; Brodows RG
    Clin Ther; 2008 Aug; 30(8):1448-60. PubMed ID: 18803987
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Impact of baseline BMI on glycemic control and weight change with metformin monotherapy in Chinese type 2 diabetes patients: phase IV open-label trial.
    Ji L; Li H; Guo X; Li Y; Hu R; Zhu Z
    PLoS One; 2013; 8(2):e57222. PubMed ID: 23468941
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.